Thursday, February 19, 2026
ISSN 2765-8767
  • Survey
  • Podcast
  • Write for Us
  • My Account
  • Log In
Daily Remedy
  • Home
  • Articles
  • Podcasts
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    July 1, 2025

    The cost structure of hospitals nearly doubles

    July 1, 2025
    Navigating the Medical Licensing Maze

    The Fight Against Healthcare Fraud: Dr. Rafai’s Story

    April 8, 2025
  • Surveys

    Surveys

    How Confident Are You in RFK Jr.’s Health Leadership?

    How Confident Are You in RFK Jr.’s Health Leadership?

    February 16, 2026
    AI in Healthcare Decision-Making

    AI in Healthcare Decision-Making

    February 1, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
  • Home
  • Articles
  • Podcasts
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    July 1, 2025

    The cost structure of hospitals nearly doubles

    July 1, 2025
    Navigating the Medical Licensing Maze

    The Fight Against Healthcare Fraud: Dr. Rafai’s Story

    April 8, 2025
  • Surveys

    Surveys

    How Confident Are You in RFK Jr.’s Health Leadership?

    How Confident Are You in RFK Jr.’s Health Leadership?

    February 16, 2026
    AI in Healthcare Decision-Making

    AI in Healthcare Decision-Making

    February 1, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
Daily Remedy
No Result
View All Result
Home Uncertainty & Complexity

When Ease-of-use is the Endpoint

Daily Remedy by Daily Remedy
January 30, 2022
in Uncertainty & Complexity
0
When Ease-of-use is the Endpoint

Sometimes how you decide matters more than what you decide. The thoughts that lead up to a decision can be more important than the decision itself. This counterintuitive notion was first discovered in the 1960’s with behavioral economists Daniel Kahneman and Amos Tversky.

They discovered the mind has – generally speaking – two patterns of thought, one fast and one slow. The slow, methodical thought process is the one that generates the most prudent decisions. But the fast process is what we mostly fall back on. And healthcare is no different.

We rely on reflexive thinking in healthcare. It is the essence of outpatient care. Patients after patients line up, waiting hours on end, spending minutes with a physician who spews the most apparent diagnosis with the most obvious treatment plan, before moving on to the next patient. Time is of the essence, so there is no time for deliberation – come in, get triaged, wait, get seen, and get on your way. The process has become so routine that we have come to accept it as standard of care.

But we never stop to question the utility of it, whether there is a better way. We simply dig our heels into this mode of thinking and press onwards. So when we think about healthcare innovations, we think in the same way, we think fast.

We rapidly identify opportunities for improvement in healthcare. We create widgets and apps to address those opportunities. And we quickly pilot them, looking for the most apparent outcome. We tout success without knowing what success is because that is what you do when you think fast. Eventually, we define success through the same way of thinking. Whatever helps to think fast is a success – regardless of whether that definition of success matters for patient care.

This explains the preponderance of meditation apps that do little more than provide an outlet for the stressed out to expressed themselves. These apps do not help with any tangible outcome, but they are easy to use – at least according to the surveys that have evaluated them. But few have tried to quantify stress and even fewer have tried to correlate stress levels with clinical outcomes. It is a matter of converting the subjective perception of stress into an objectively defined clinical metric – something often dismissed like a cheap magic trick because it does not jive with thinking fast in healthcare.

We like easy in and easy out. We measure success with tangible data that can be measured and compared – one input to one output – and like that, we are done. But when we apply that mindset over and over in healthcare, we find that the way we think has very little to do with the essence of healthcare.

Everything that is wrong with thinking fast is encapsulated by the Alzheimer’s drug, Adulheim. No clinical symptom or lifestyle metric was evaluated in the drug trial. No clinical correlation was drawn to data. Instead, the drug manufacturer submitted data showing how the drug reduces a protein marker, Beta Amyloid, which inconsistently correlates with the clinical symptoms of dementia.

What is a disease if not the symptoms it presents in a patient?

In our lust to quantify all things healthcare, we altered how we think about clinical care. We gravitate towards the discrete because that allows us to think fast. But in our rush to think fast, we gravitate towards convenient endpoints.

The pandemic has made it clear that healthcare is a system. The midpoints are as important as the perceived endpoints. When thinking in systems, there is no need to think fast because the process matters more than the decision. This might be a good thing because healthcare has had enough of thinking fast – especially during the pandemic.

Healthcare lost much of its credibility from studies with outcomes that were premature and from pre-published clinical studies lacking the appropriate analysis for accuracy. These are fast thinking problems. In our haste, we lost the prudence that comes with scientific rigor.

We should start thinking slow. We may end up making the same decisions, but at least how we get there will be more sensible.

ShareTweet
Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Videos

This conversation focuses on debunking myths surrounding GLP-1 medications, particularly the misinformation about their association with pancreatic cancer. The speaker emphasizes the importance of understanding clinical study designs, especially the distinction between observational studies and randomized controlled trials. The discussion highlights the need for patients to critically evaluate the sources of information regarding medication side effects and to empower themselves in their healthcare decisions.

Takeaways
GLP-1 medications are not linked to pancreatic cancer.
Peer-reviewed studies debunk misinformation about GLP-1s.
Anecdotal evidence is not reliable for general conclusions.
Observational studies have limitations in generalizability.
Understanding study design is crucial for evaluating claims.
Symptoms should be discussed in the context of clinical conditions.
Not all side effects reported are relevant to every patient.
Observational studies can provide valuable insights but are context-specific.
Patients should critically assess the relevance of studies to their own experiences.
Engagement in discussions about specific studies can enhance understanding

Chapters
00:00
Debunking GLP-1 Medication Myths
02:56
Understanding Clinical Study Designs
05:54
The Role of Observational Studies in Healthcare
Debunking Myths About GLP-1 Medications
YouTube Video DM9Do_V6_sU
Subscribe

2027 Medicare Advantage & Part D Advance Notice

Clinical Reads

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

by Daily Remedy
February 15, 2026
0

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!

Twitter Updates

Tweets by TheDailyRemedy

Popular

  • The Prevention Gap in Dementia Care

    The Prevention Gap in Dementia Care

    0 shares
    Share 0 Tweet 0
  • Healthcare in Space

    1 shares
    Share 0 Tweet 0
  • Heat Safety Tips Every Pregnant Mother Should Know

    0 shares
    Share 0 Tweet 0
  • Child Health Is Now a Platform Issue

    0 shares
    Share 0 Tweet 0
  • The Quiet Clinical Coup of Artificial Intelligence

    0 shares
    Share 0 Tweet 0
  • 628 Followers

Daily Remedy

Daily Remedy offers the best in healthcare information and healthcare editorial content. We take pride in consistently delivering only the highest quality of insight and analysis to ensure our audience is well-informed about current healthcare topics - beyond the traditional headlines.

Daily Remedy website services, content, and products are for informational purposes only. We do not provide medical advice, diagnosis, or treatment. All rights reserved.

Important Links

  • Support Us
  • About Us
  • Contact us
  • Privacy Policy
  • Terms and Conditions

Join Our Newsletter!

  • Survey
  • Podcast
  • About Us
  • Contact us

© 2026 Daily Remedy

No Result
View All Result
  • Home
  • Articles
  • Podcasts
  • Surveys
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner

© 2026 Daily Remedy